In consideration of the pivotal role of PNPLA3 variants in the pathogenesis of MASLD, PMS may indeed be considered a model disease that will allow researchers and physicians to explore dysmetabolic dynamics and identify molecular targets for potential treatment development. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.